First-time imaging of [Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner.
作者信息
Brouwers Adrienne H, van Sluis Joyce, van Snick Johannes H, Schröder Carolina P, Baas Inge O, Boellaard Ronald, Glaudemans Andor W J M, Borra Ronald J H, Lammertsma Adriaan A, Dierckx Rudi A J O, Tsoumpas Charalampos
机构信息
University of Groningen, University Medical Center Groningen, Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, PO Box 30001, 9700 RB, Groningen, The Netherlands.
Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands.
出版信息
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3593-3595. doi: 10.1007/s00259-022-05777-x. Epub 2022 Apr 1.
Abstract
摘要
相似文献
1
First-time imaging of [Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner.
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3593-3595. doi: 10.1007/s00259-022-05777-x. Epub 2022 Apr 1.
2
Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Zr-Labeled Trastuzumab-DM1: A Comparison with Zr-Labeled Trastuzumab.
Mol Pharm. 2018 Aug 6;15(8):3383-3393. doi: 10.1021/acs.molpharmaceut.8b00392. Epub 2018 Jul 16.
3
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for Zr-Trastuzumab.
J Nucl Med. 2023 Nov;64(11):1815-1820. doi: 10.2967/jnumed.123.265621. Epub 2023 Aug 3.
4
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
Clin Pharmacol Ther. 2010 May;87(5):586-92. doi: 10.1038/clpt.2010.12. Epub 2010 Mar 31.
5
[Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.
Mol Imaging Biol. 2016 Dec;18(6):952-959. doi: 10.1007/s11307-016-0951-z.
6
Evaluation of [Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13.
7
Tumor uptake and tumor/blood ratios for [Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1.
Nucl Med Biol. 2018 Dec;67:43-51. doi: 10.1016/j.nucmedbio.2018.10.002. Epub 2018 Oct 16.
8
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.
9
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
J Nucl Med. 2016 Oct;57(10):1523-1528. doi: 10.2967/jnumed.115.172031. Epub 2016 May 5.
10
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging.
Breast Cancer Res. 2018 Oct 25;20(1):130. doi: 10.1186/s13058-018-1055-2.
引用本文的文献
1
Clinical Performance Comparison of a Long Versus a Short Axial Field-of-View PET/CT Using EARL-Compliant Reconstructions.
Mol Imaging Biol. 2024 Oct;26(5):780-789. doi: 10.1007/s11307-024-01939-5. Epub 2024 Aug 2.
2
Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.
Int J Mol Sci. 2024 Jan 26;25(3):1575. doi: 10.3390/ijms25031575.
3
Marriage of radiotracers and total-body PET/CT rapid imaging system: current status and clinical advances.
Am J Nucl Med Mol Imaging. 2023 Oct 20;13(5):195-207. eCollection 2023.
4
Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology.
Cancers (Basel). 2023 Oct 27;15(21):5173. doi: 10.3390/cancers15215173.
5
Characterization of the partial volume effect along the axial field-of-view of the Biograph Vision Quadra total-body PET/CT system for multiple isotopes.
EJNMMI Phys. 2023 May 27;10(1):33. doi: 10.1186/s40658-023-00554-7.
6
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies.
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3354-3362. doi: 10.1007/s00259-023-06222-3. Epub 2023 Apr 20.
7
Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients.
Cancer Imaging. 2023 Mar 18;23(1):28. doi: 10.1186/s40644-023-00540-3.
8
Molecular Imaging Diagnosis of Renal Cancer Using Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques.
Diagnostics (Basel). 2023 Feb 6;13(4):593. doi: 10.3390/diagnostics13040593.
9
Will extended field-of-view PET/CT depopulate the graveyard of failed PET radiopharmaceuticals?
Cancer Imaging. 2022 Dec 19;22(1):70. doi: 10.1186/s40644-022-00510-1.
10
Extending the clinical capabilities of short- and long-lived positron-emitting radionuclides through high sensitivity PET/CT.
Cancer Imaging. 2022 Dec 16;22(1):69. doi: 10.1186/s40644-022-00507-w.
本文引用的文献
1
Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard.
J Nucl Med. 2022 Mar;63(3):476-484. doi: 10.2967/jnumed.121.261972. Epub 2021 Jul 22.
2
Long axial field of view PET scanners: a road map to implementation and new possibilities.
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4236-4245. doi: 10.1007/s00259-021-05461-6. Epub 2021 Jun 16.
3
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner.
J Nucl Med. 2019 Mar;60(3):299-303. doi: 10.2967/jnumed.119.226498. Epub 2019 Feb 7.
4
Feasibility of PET/CT system performance harmonisation for quantitative multicentre Zr studies.
EJNMMI Phys. 2018 Nov 21;5(1):26. doi: 10.1186/s40658-018-0226-7.
5
Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30.
6
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. doi: 10.1007/s00259-014-2961-x. Epub 2014 Dec 2.
7
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
Clin Pharmacol Ther. 2010 May;87(5):586-92. doi: 10.1038/clpt.2010.12. Epub 2010 Mar 31.
Zotero 插件